v. 4, n. 47, 2024

International Journal of Health Science

CLINICAL INSIGHTS INTO PAIN SENSITIVITY: A NARRATIVE REVIEW OF HYPOSENSITIVITY

Rebeca Maida Sabbag Barbosa
http://lattes.cnpq.br/3699079180938167

Joaquim Custodio Faria Filho
http://lattes.cnpq.br/4679157854226093

Luís Miguel Amaral Silva
http://lattes.cnpq.br/0012035418018212

Gabriella Maia Barbosa
http://lattes.cnpq.br/0511381972249972

Raíssa poletto maluf Amaral
http://lattes.cnpq.br/9669003401155294

Victor Hugo Zanardi Anunciação
http://lattes.cnpq.br/4791743372358340

Letícia Ferreira Feitosa
http://lattes.cnpq.br/4791743372358340

Thaís Pedra Oliveira
http://lattes.cnpq.br/1775620856113583

Mariana Chiavelli Oliveira
https://wwws.cnpq.br/cvlattesweb/PKG_MENU.menu?f_cod=6F2A88EEF-00880F9076A431CE12E3D64#

Fiamma Aricia da Silva Cerqueira
http://lattes.cnpq.br/7519451011856957

Maria vitoria de almeida petris
http://lattes.cnpq.br/3328267291723665

Mauricio Lopes da Silva Netto
http://lattes.cnpq.br/4791743372358340

Abstract: INTRODUCTION Pain is a crucial biological signal that indicates potential harm, involving complex sensory processes that interpret severity and nature of pain through specific brain regions. Chronic pain affects about 20% of the global population, imposing significant economic and healthcare costs. Pain types vary from acute, which directly signals tissue damage, to chronic and neuropathic pains, each requiring distinct management strategies. Effective pain management is essential across all medical fields and extends to disciplines like psychology and ergonomics, emphasizing its universal impact on health and productivity. **OBJETIVE** To analyze and describe the main aspects of the different forms of hypoanesthesia and loss of sensitivity in recent years. **METHODS** This is a narrative review which included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases, using as descriptors: "Congenital Insensitivity to Pain" AND "Hereditary Sensory and Autonomic Neuropathy" AND "Paroxysmal Extreme Pain Disorder" AND "Chemotherapy-induced Peripheral Neuropathy" AND "Pharmacological Modulation of Sensory Perception" in the last years. **RESULTS AND DISCUSSION** The study and management of pain, particularly in conditions involving hyposensitivity or an absence of pain sensation like Congenital Insensitivity to Pain (CIP) and Hereditary Sensory and Autonomic Neuropathy (HSAN), present profound clinical challenges. These disorders often lead to high risks of unnoticed injuries and infections due to the absence of pain feedback mechanisms. Management requires an in-depth understanding of the genetic factors involved, particularly mutations affecting the SCN9A gene linked to pain signal transduction, and tailored interventions aimed at preventing complications. Conditions like diabetic neuropathy and HIV-associated neuropathy further illustrate the complexity of pain management in cases of reduced pain sensitivity, demanding comprehensive strategies to address both the direct and secondary impacts of diminished pain perception. Additionally, the review underlines the importance of vigilant clinical practices and patient education to mitigate the risks associated with pharmacologically induced sensory alterations in pain perception. Effective pain management is crucial across all medical specialties and is necessary for improving patient outcomes in a broad spectrum of health conditions. **CONCLUSION** The narrative review thoroughly examines the challenges in managing congenital, acquired, and pharmacologically induced hyposensitivity to pain, underscoring the need for a deep genetic understanding, vigilant monitoring, and interdisciplinary care to prevent unnoticed injuries and complications. It also explores the complexities of acquired disorders like diabetic and HIV-associated neuropathy, requiring integrated approaches that combine rigorous disease management with proactive preventive measures against sensory impairments. Furthermore, the review delves into the risks associated with pharmacological agents used in pain management and anesthesia, advocating for precise dosing, strict monitoring, and comprehensive patient education to mitigate potential injuries and enhance patient safety.

Keywords: Anesthesiology; Pain; Quality of life; Pharmacology

INTRODUCTION

Pain is fundamentally a complex sensation that serves as a critical component of the body's defense mechanism, alerting to potential harm[1]. It is generally described as an unpleasant sensory and emotional experience associated with actual or potential tissue damage, or described in terms of such damage, per the International Association for the Study of Pain[2]. Pain perception, or nociception, involves the transduction, transmission, modulation, and perception of noxious stimuli[3]. These processes engage various physiological pathways and brain regions to interpret the intensity and nature of pain[4]. This subjective experience varies widely not only among individuals but also in the same individual, depending on psychological and environmental factors[4,5].

Epidemiologically, pain is a predominant symptom in the general population, significantly affecting quality of life and economic stability[6]. Chronic pain, as one of the most common reasons adults seek medical care, impacts an estimated 20% of people worldwide and contributes to substantial healthcare utilization and disability[7]. In economic terms, the burden of chronic pain is immense, with the costs associated with medical care and lost productivity amounting to several hundred billion dollars annually in the United States alone[8,9]. This economic strain reflects both direct costs such as healthcare expenditures and indirect costs including lost workdays and decreased productivity[10,11].

The physiology of pain is rooted in the neural pathways that transmit pain signals from the periphery to the central nervous system[11,12]. Nociceptive signals are picked up by specialized receptors and carried through peripheral nerves to the spinal cord, where they ascend to the brain[12]. The primary regions involved in processing pain include the thalamus, which acts as a relay station, and the cerebral cortex, which interprets the pain's location, intensity, and quality. Furthermore, the limbic system integrates the emotional aspects associated with pain experiences[13]. Neurotransmitters and modulators, such as glutamate and substance P, play crucial roles in the amplification and suppression of pain signals within these pathways[14,15,16].

Pain can be categorized into several types, each with distinct characteristics and origins[17]. Acute pain, typically sharp and sudden, acts as a direct signal of tissue damage and usually resolves once the injury heals[18]. Chronic pain, in contrast, persists beyond the normal healing time and often lacks a clear cause[19,20]. Neuropathic pain arises from damage to the nervous system itself, leading to pain that is often described as burning, shooting, or tingling. Visceral pain originates from the internal organs and is frequently more diffuse and challenging to localize[23]. Inflammatory pain occurs in response to tissue damage and inflammation, involving an array of biochemical changes that enhance sensitivity to pain[22].

Pain's relevance transcends all medical specialties, underscoring its importance not only in clinical medicine but also in fields such as psychology, physiotherapy, and even occupational health[24,25]. Effective pain management is pivotal in surgical recovery, chronic disease management, cancer care, and end-of-life care, impacting outcomes and patient satisfaction[26]. Additionally, understanding pain mechanisms and management strategies is critical in non-medical fields like ergonomics and sports science, where pain prevention and management are vital for enhancing performance and preventing injury[27].

OBJETIVES

To analyze and describe the main aspects of the different forms of hypoanesthesia and loss of sensitivity in recent years.

SECUNDARY OBJETIVES

1. To explore the genetic and clinical manifestations of disorders like Congenital Insensitivity to Pain (CIP) and Hereditary Sensory and Autonomic Neuropathy (HSAN), which result in diminished or absent pain sensations due to mutations in genes such as SCN9A.

2. To analyze conditions like diabetic neuropathy, leprosy, HIV-associated neuropathy, chemotherapy-induced peripheral neuropathy, spinal cord injuries, and multiple sclerosis, focusing on how they lead to reduced pain sensitivity through nerve damage or systemic disease processes.

3. To review the effects of drugs like opioids, benzodiazepines, general anesthetics, barbiturates, anticonvulsants, local anesthetics, and alcohol on pain perception, highlighting the risk of hyposensitivity and the clinical implications for patient safety.

4. To investigate the types, prevalence, and preventive strategies of iatrogenic injuries during anesthesia, including mechanical, drug-induced, and procedural complications.

5. To discuss the complications of diabetes mellitus in anesthesia, such as altered drug metabolism, increased infection risks, and challenges in wound healing, to enhance perioperative care.

6. To address specific perioperative challenges and strategies for patients with conditions that impair pain sensation, including tailored anesthesia plans, advancements in monitoring techniques, and the legal and ethical implications of iatrogenic injuries.

METHODS

This is a narrative review, in which the main aspects of the different forms of hypoanesthesia and loss of sensitivity in recent years were analyzed. The beginning of the study was carried out with theoretical training using the following databases: PubMed, sciELO and Medline, using as descriptors: "Congenital Insensitivity to Pain" AND "Hereditary Sensory and Autonomic Neuropathy" AND "Paroxysmal Extreme Pain Disorder" AND "Chemotherapy-induced Peripheral Neuropathy" AND "Pharmacological Modulation of Sensory Perception" in the last years. As it is a narrative review, this study does not have any risks.

Databases: This review included studies in the MEDLINE – PubMed (National Library of Medicine, National Institutes of Health), COCHRANE, EMBASE and Google Scholar databases.

The inclusion criteria applied in the analytical review were human intervention studies, experimental studies, cohort studies, case-control studies, cross-sectional studies and literature reviews, editorials, case reports, and poster presentations. Also, only studies writing in English and Portuguese were included.

RESULTS AND DISCUSSION

The complexity of diagnosing and managing patients with hyposensitivity or an absence of pain sensation presents a significant challenge in the field of pain medicine[28]. Conditions such as Congenital Insensitivity to Pain (CIP) and various types of Hereditary Sensory and Autonomic Neuropathy (HSAN) not only predispose individuals to high risks of unnoticed injuries and infections but also complicate routine medical and surgical care[28,29]. Furthermore, understanding the nuances of these disorders is crucial for developing effective preventive strategies and therapeutic interventions[28,29,30].

Congenital Insensitivity to Pain is a paradigmatic example, characterized by mutations in the SCN9A gene, which encodes the NaV1.7 sodium channel pivotal for pain signal transduction[31]. The absence of functional NaV1.7 channels results in a complete lack of pain perception, often leading patients to sustain severe injuries and repeated burns without the protective pain response[32]. This condition, though rare, underscores the critical role of genetic factors in sensory perception and provides a framework for studying other sensory neuropathies[33]. Clinical management requires not only vigilant surveillance for injuries and infections but also a multidisciplinary approach to care, which may include physical therapy and specialized educational programs to teach injury prevention strategies[34].

HSAN encompasses a group of disorders with variable presentations, ranging from mild sensory deficits to complete absence of pain perception, often accompanied by autonomic dysfunction[34,35]. HSAN Type I typically manifests with sensory loss in the distal extremities, posing significant risks for unnoticed injuries, which may lead to chronic ulcers or osteomyelitis[36]. The more severe HSAN Type II is characterized by an early onset of symptoms, significantly increasing the risk of self-mutilation and joint deformities, often diagnosed in infancy. HSAN Type III, or Riley-Day Syndrome, includes temperature insensitivity and autonomic irregularities, complicating the clinical picture with episodic hypertension and potential for life-threatening crises[37]. HSAN Type IV and V are particularly challenging due to the additional complications of anhidrosis and dysregulation of body temperature, necessitating constant monitoring and interventions to manage hyperthermia[38].

Paroxysmal Extreme Pain Disorder, although involving mutations in the same SCN9A gene as CIP, presents with episodic severe pain rather than insensitivity, highlighting the gene's critical role in modulating pain thresholds[39,40]. This condition provides insight into the genetic underpinnings of pain regulation and offers opportunities for targeted genetic therapies that could ameliorate or even prevent the severe episodes of pain associated with the disorder[41,42].

For pain specialists, the management of these conditions requires an in-depth understanding of both the genetic basis and the phenotypic manifestations of each disorder[43]. The approach to treatment must be tailored not only to alleviate or manage symptoms but also to prevent the numerous complications that arise from the lack of natural protective pain responses[44]. This includes regular and meticulous physical examinations, use of protective equipment to prevent skin and bone injuries, and patient and family education on the importance of early injury detection[44,45,46].

Understanding the implications of acquired disorders that lead to altered pain sensitivity is paramount for the effective management and prevention of injuries in affected individuals[47]. These conditions, ranging from metabolic diseases like diabetic neuropathy to infectious diseases such as leprosy and HIV-associated neuropathy, present unique challenges in clinical practice[48,49]. This review discusses the implications of such disorders, focusing on the risks and preventive strategies associated with diminished pain sensitivity[49].

Diabetic neuropathy represents one of the most prevalent acquired causes of sensory impairment, affecting millions globally[50]. Prolonged hyperglycemia leads to structural and functional changes in peripheral nerves, resulting in a gradual loss of sensory function, particularly in the lower extremities[51]. This insidious decrease in pain perception significantly heightens the risk of

unnoticed injuries, infections, and subsequent complications such as foot ulcers and Charcot joints, which can lead to severe disability and even amputation[52]. Effective management strategies are critical and include rigorous glycemic control combined with regular foot inspections and use of protective footwear to mitigate injury risk[54].

Leprosy, or Hansen's Disease, is another condition where nerve damage can lead to a significant reduction in pain sensitivity[54,55]. The disease primarily affects skin and peripheral nerves, leading to the classic presentation of numb patches of skin[55]. The loss of sensation in these areas predisposes individuals to burns, wounds, and secondary infections[55]. Management in leprosy is multifaceted, focusing not only on the antimicrobial treatment of the disease but also on the prevention of injury and rehabilitation strategies to enhance function and quality of life[56].

HIV-associated neuropathy also poses considerable challenges[56]. Both the virus itself and the antiretroviral treatment can contribute to the development of peripheral neuropathy, characterized by sensory loss, which can be further compounded by co-existing conditions such as diabetes or vitamin B12 deficiency[57]. The management of HIV-associated neuropathy involves optimizing HIV therapy to minimize drug-related neurotoxicity, appropriate use of analgesics, and supportive measures such as nutritional supplementation[52,56,57].

Chemotherapy-induced peripheral neuropathy (CIPN) is an increasingly recognized problem as cancer survivorship improves[58]. Agents such as platinum compounds, taxanes, and vinca alkaloids are known to cause peripheral nerve damage, manifesting as pain, numbness, or sensory alterations in a "stocking-glove" distribution[54,57]. The prevention and management of CIPN are challenging; dose modification and the use of neuroprotective agents may be beneficial, although evidence is limited. Early recognition and management of symptoms are crucial to prevent long-term disability[56,58].

Spinal cord injuries (SCI) depending on the level and severity, can lead to partial or complete loss of sensation below the level of injury[59]. This lack of sensation dramatically increases the risk of pressure sores and other injuries that are not felt by the patient[57]. Rehabilitation and regular monitoring are integral to care, focusing on skin integrity and mobility to prevent complications[59].

Multiple Sclerosis (MS), a demyelinating disease of the central nervous system, can intermittently affect sensory nerves, including those responsible for pain perception[60]. The fluctuating nature of MS makes management particularly challenging, requiring tailored therapies to manage the neurologic symptoms effectively and prevent complications related to sensory deficits[60].

The administration of pharmacological agents that modulate sensory perceptions, particularly pain sensitivity, is a fundamental aspect of clinical practice, especially in fields requiring anesthesia or intensive pain management[61]. However, the inherent risk associated with these drugs, including potential hyposensitivity or an absence of sensation, necessitates a comprehensive understanding and careful management to prevent inadvertent injuries among patients[61]. This review explores the implications of commonly used pharmacological agents that can induce sensory modulation, focusing on their mechanisms, potential risks, and the clinical strategies employed to mitigate these effects[62].

Opioids, such as morphine, fentanyl, oxycodone, and hydrocodone, represent a class of potent analgesics widely utilized for their

efficacy in pain relief[62,63]. While indispensable in managing severe pain, opioids may also diminish broader sensory perceptions, especially when used in high doses or over prolonged periods[60, 62]. The resultant sensory impairment can mask injury symptoms, leading to delayed diagnoses and treatment. It is imperative for clinicians to balance opioid dosing and monitor patients closely, adjusting treatment based on individual responses to minimize the risk of unnoticed injuries[63].

Benzodiazepines, including diazepam, lorazepam, and alprazolam, are primarily employed for their anxiolytic and sedative effects[63]. Besides their central nervous system depressant activity, these agents can dull sensory perception, including pain[64]. This can be particularly concerning in settings where patients may not effectively communicate discomfort or injuries, such as in geriatric care or psychiatry. Vigilance in monitoring and dosage adjustments is essential to avoid complications arising from sensory dulled by benzodiazepines[62,64].

General anesthetics like propofol, isoflurane, and sevoflurane are critical in surgical settings for inducing a controlled and reversible loss of consciousness and sensation[60,62]. While these drugs are effective in preventing intraoperative pain and discomfort, their profound impact on sensory perception increases the risk of postoperative complications, such as unrecognized injuries or inadequate pain management following the return of sensation[55,64]. Protocols for perioperative monitoring and postoperative care must be meticulously designed to ensure patient safety and optimize recovery[60,62,64].

Barbiturates, though less commonly used today due to their high risk of dependency and severe side effects, including overdose, still play a role in certain medical scenarios[65]. Drugs such as phenobarbital and thiopental significantly impair sensory perceptions and require careful administration and monitoring, particularly in emergency settings or in the treatment of severe seizures where alternative treatments are not viable[62,65].

Anticonvulsants and neuropathic pain agents, like gabapentin, pregabalin, and carbamazepine, are used to manage conditions characterized by abnormal nerve function[66]. While these medications are effective in reducing neuropathic pain, they may also cause hyposensitivity in other sensory domains[66]. Clinicians must be aware of these side effects, which can complicate the clinical picture, particularly in patients with pre-existing neuropathies or in those receiving multi-drug regimens[58,65,67].

Local anesthetics such as lidocaine, bupivacaine, and ropivacaine are indispensable in procedures requiring localized pain control[68]. While highly effective in blocking nerve transmission in targeted areas, there is a risk of systemic toxicity if used improperly[64,68]. Ensuring appropriate dosing and employing techniques that minimize systemic absorption are crucial to prevent complications[51,64,68].

Lastly, alcohol, although not a prescribed drug, merits attention due to its prevalent use and potential to significantly impair sensory and motor functions at high doses[69]. The acute effects of alcohol can mask pain and other sensations, leading to unrecognized injuries. Awareness and education about the risks of alcohol consumption, particularly in settings of acute care or injury, are vital[54,68,69].

CONCLUSION

The exploration of hyposensitivity and insensitivity to pain due to various congenital, acquired, and pharmacologically induced conditions underscores a complex domain within pain medicine, challenging clinicians to employ meticulous care and prevention strategies. The narrative review provides compelling insights into the management of

these conditions and the urgent necessity for tailored interventions.

Genetic disorders such as Congenital Insensitivity to Pain and Hereditary Sensory and Autonomic Neuropathies elucidate the critical importance of understanding the genetic underpinnings and clinical manifestations of pain insensitivity. These conditions not only predispose patients to unnoticed injuries and severe complications but also necessitate a comprehensive, multidisciplinary approach to care—ranging from vigilant surveillance for injuries to educational programs aimed at preventing such injuries.

Moreover, the discussion on acquired disorders, including diabetic neuropathy and HIV-associated neuropathy, highlights the intricate link between systemic diseases and sensory impairments. These conditions present unique challenges, requiring clinicians to integrate rigorous disease management with proactive measures to prevent injury and manage pain sensitivity effectively. Pharmacological agents, particularly those used in pain management and anesthesia, pose risks of inducing hyposensitivity, which can lead to delayed injury detection and management. This review emphasizes the need for precise dosing, close monitoring, and patient education to mitigate these risks effectively.

REFERENCES

1. Merskey H, Bogduk N. Classification of Chronic Pain, Second Edition, IASP Task Force on Taxonomy. Seattle: IASP Press; 1994.

2. Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012;13(8):715-24.

3. Treede RD, Rief W, Barke A, et al. A classification of chronic pain for ICD-11. Pain. 2015;156(6):1003-7.

4. Basbaum AI, Bautista DM, Scherrer G, Julius D. Cellular and molecular mechanisms of pain. Cell. 2009;139(2):267-84.

5. Woolf CJ. Central sensitization: Implications for the diagnosis and treatment of pain. Pain. 2011;152(3 Suppl):S2-15.

6. Jensen TS, Baron R. Translation of symptoms and signs into mechanisms in neuropathic pain. Pain. 2003;102(1-2):1-8.

7. Loeser JD, Treede RD. The Kyoto protocol of IASP Basic Pain Terminology. Pain. 2008;137(3):473-7.

8. Woolf CJ, Ma Q. Nociceptors—Noxious Stimulus Detectors. Neuron. 2007;55(3):353-64.

9. Gold MS, Gebhart GF. Nociceptor sensitization in pain pathogenesis. Nat Med. 2010;16(11):1248-57.

10. Ji RR, Nackley A, Huh Y, Terrando N, Maixner W. Neuroinflammation and Central Sensitization in Chronic and Widespread Pain. Anesthesiology. 2018;129(2):343-66.

11. Costigan M, Scholz J, Woolf CJ. Neuropathic Pain: A Maladaptive Response of the Nervous System to Damage. Annu Rev Neurosci. 2009;32:1-32.

12. Tracey I, Mantyh PW. The Cerebral Signature for Pain Perception and Its Modulation. Neuron. 2007;55(3):377-91.

13. Purves D, Augustine GJ, Fitzpatrick D, et al., editors. Neuroscience. 5th ed. Sunderland, MA: Sinauer Associates; 2012.

14. Yarnitsky D. Conditioned pain modulation (the diffuse noxious inhibitory control-like effect): its relevance for acute and chronic pain states. Pain. 2010;150(3):573-81.

15. Apkarian AV, Hashmi JA, Baliki MN. Pain and the brain: Specificity and plasticity of the brain in clinical chronic pain. Pain. 2011;152(3 Suppl):S49-64.

16. Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19.

17. Melzack R, Wall PD. Pain mechanisms: a new theory. Science. 1965;150(3699):971-9.

18. Sindrup SH, Jensen TS. Pharmacotherapy of trigeminal neuralgia. Clin J Pain. 2002;18(1):22-7.

19. Fields HL, Basbaum AI, Heinricher MM. Central Nervous System Mechanisms of Pain Modulation. In: McMahon SB, Koltzenburg M, Tracey I, Turk DC, editors. Wall and Melzack's Textbook of Pain. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013. p. 129-42.

20. McMahon SB, Koltzenburg M, Tracey I, Turk DC, editors. Wall and Melzack's Textbook of Pain. 6th ed. Philadelphia, PA: Elsevier Saunders; 2013.

21. International Association for the Study of Pain. IASP Terminology. [Internet]. Available from: https://www.iasp-pain.org/Education/Content.aspx?ItemNumber=1698#Pain

22. Turk DC, Wilson HD, Cahana A. Treatment of chronic non-cancer pain. Lancet. 2011;377(9784):2226-35.

23. Chapman CR, Vierck CJ. The Transition of Acute Postoperative Pain to Chronic Pain: An Integrative Overview of Research on Mechanisms. J Pain. 2017;18(4):359.e1-359.e38.

24. Lenz FA, Casey KL, Jones EG, Willis WD, editors. The Human Pain System: Experimental and Clinical Perspectives. Cambridge: Cambridge University Press; 2010.

25. Kandel ER, Schwartz JH, Jessell TM, Siegelbaum S, Hudspeth AJ, Mack S. Principles of Neural Science. 5th ed. New York, NY: McGraw Hill; 2013.

26. Latremoliere A, Woolf CJ. Central Sensitization: A Generator of Pain Hypersensitivity by Central Neural Plasticity. J Pain. 2009;10(9):895-926.

27. Davis KD, Moayedi M. Central Mechanisms of Pain Revealed Through Functional and Structural MRI. J Neuroimmune Pharmacol. 2013;8(3):518-34.

28. Nagasako EM, Oaklander AL, Dworkin RH. Congenital insensitivity to pain: an update. Pain. 2003 Feb;101(3):213-9.

29. Axelrod FB, Gold-von Simson G. Hereditary sensory and autonomic neuropathies: types II, III, and IV. Orphanet J Rare Dis. 2007 Oct 2;2:39.

30. Waxman SG, Merkies ISJ, Gerrits MM. Sodium channel genes in pain-related disorders: phenotype-genotype associations and recommendations for clinical use. Lancet Neurol. 2014 Nov;13(11):1152-60.

31. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care. 2010;33(10):2285-93.

32. Scollard DM, Adams LB, Gillis TP, et al. The continuing challenges of leprosy. Clin Microbiol Rev. 2006;19(2):338-81.

33. Phillips TJ, Cherry CL, Cox S, et al. Pharmacological treatment of painful HIV-associated sensory neuropathy: a systematic review and meta-analysis of randomised controlled trials. PLoS One. 2010;5(12):e14433.

34. Park SB, Goldstein D, Krishnan AV, et al. Chemotherapy-induced peripheral neurotoxicity: a critical analysis. CA Cancer J Clin. 2013;63(6):419-37.

35. Kalso E, Edwards JE, Moore RA, McQuay HJ. Opioids in chronic non-cancer pain: systematic review of efficacy and safety. Pain. 2004;112(3):372-380.

36. Smith HS. Opioid metabolism. Mayo Clin Proc. 2009;84(7):613-624.

37. Patel R, Dickenson AH. Mechanisms of the gabapentinoids and α2δ-1 calcium channel subunit in neuropathic pain. Pharmacol Res Perspect. 2016;4(2):e00205.

38. Yaksh TL, Wallace MS. Opioids, analgesia, and pain management. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 12th ed. New York: McGraw-Hill; 2011. p. 481-526.

39. McQuay HJ, Tramèr M, Nye BA, Carroll D, Wiffen PJ, Moore RA. A systematic review of antidepressants in neuropathic pain. Pain. 1996;68(2-3):217-227.

40. National Spinal Cord Injury Statistical Center. Spinal Cord Injury Facts and Figures at a Glance. 2020. Available at: [URL]

41. Boulton AJM, Vinik AI, Arezzo JC, et al. Diabetic neuropathies: a statement by the American Diabetes Association. Diabetes Care. 2005;28(4):956-62.

42. Rambukkana A. Mechanisms of nerve damage in leprosy. Clin Dermatol. 2016;34(1):36-43.

43. Simpson DM, Kitch D, Evans SR, et al. HIV neuropathy natural history cohort study: assessment measures and risk factors. Neurology. 2006;66(11):1679-87.

44. Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer. 2006;42(1):24-30.

45. Jensen MP, Chodroff MJ, Dworkin RH. The impact of neuropathic pain on health-related quality of life: review and implications. Neurology. 2007;68(15):1178-82.

46. Cousins MJ, Bridenbaugh PO. Neural Blockade in Clinical Anesthesia and Pain Medicine. 4th ed. Philadelphia: Lippincott Williams & Wilkins; 2008.

47. Frohman EM, Racke MK, Raine CS. Multiple sclerosis—the plaque and its pathogenesis. N Engl J Med. 2006;354(9):942-55.

48. Bril V, England J, Franklin GM, et al. Evidence-based guideline: Treatment of painful diabetic neuropathy—report of the American Academy of Neurology, the American Association of Neuromuscular and Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Neurology. 2011;76(20):1758-65.

49. Skopelitis EE, Kokotis PI, Kontos AN, et al. Leprosy neuropathy: clinical presentations, disease mechanisms and therapeutic approaches. Lepr Rev. 2015;86(3):259-69.

50. Schütz SG, Robinson-Papp J. HIV-related neuropathy: current perspectives. HIV AIDS (Auckl). 2013;5:243-51.

51. Mercadante S. Opioid metabolism and clinical aspects. Eur J Pharmacol. 2015;769:71-78.

52. Griffiths RR, Johnson MW. Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry. 2005;66 Suppl 9:31-41.

53. Miller RD, Eriksson LI, Fleisher LA, et al. Miller's Anesthesia. 8th ed. Philadelphia, PA: Elsevier Saunders; 2015.

54. Bell RF, Dahl JB, Moore RA, Kalso E. Perioperative ketamine for acute postoperative pain. Cochrane Database Syst Rev. 2006;(1):CD004603.

55. Peckham AM, Fairman KA, Sclar DA. Prevalence of gabapentin abuse: comparison with agents with known abuse potential in a commercially insured US population. Clin Drug Investig. 2017;37(8):763-773

56. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010;150(3):573-581.

57. Ballantyne JC, Mao J. Opioid therapy for chronic pain. N Engl J Med. 2003;349(20):1943-1953.

58. Bounes V, Charpentier S, Houze-Cerfon CH, Bellard S, Ducassé JL. Are benzodiazepines associated with a higher risk of complications? A retrospective study. Emerg Med J. 2011;28(9):776-779.

59. Ropper AH, Samuels MA, Klein JP. Adams and Victor's Principles of Neurology. 10th ed. New York: McGraw-Hill Education; 2014.

60. Barry PJ, Gallagher P, Ryan C, O'Mahony D. START (screening tool to alert doctors to the right treatment)—an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36(6):632-638.

61. Watkins PB, Kaplowitz N, Slattery JT, et al. Aminotransferase elevations in healthy adults receiving 4 grams of acetaminophen daily: a randomized controlled trial. JAMA. 2006;296(1):87-93.

62. Hemmings HC Jr, Egan TD, editors. Pharmacology and Physiology for Anesthesia: Foundations and Clinical Application. 2nd ed. Philadelphia: Elsevier; 2019.

63. Gilron I, Bailey JM, Tu D, Holden RR, Weaver DF, Houlden RL. Morphine, gabapentin, or their combination for neuropathic pain. N Engl J Med. 2005;352(13):1324-1334.

64. Patorno E, Bohn RL, Wahl PM, et al. Anticonvulsant medications and the risk of suicide, attempted suicide, or violent death. JAMA. 2010;303(14):1401-1409.

65. Morgan CJ, Curran HV. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl). 2006;188(4):408-424.

66. Schug SA, Zech D, Dorr U. Cancer pain management according to WHO analgesic guidelines. J Pain Symptom Manage. 1990;5(1):27-32.

67. Sevoflurane. In: Sweetman SC, editor. Martindale: The Complete Drug Reference. 36th ed. London: Pharmaceutical Press; 2009. p. 1525-1526.

68. Tolliver BK, Anton RF. Abuse liability of benzodiazepines. Pharmacol Biochem Behav. 2015;123:103-112.

69. Schwartz TL, Nihalani N, Jindal S, Virk S, Jones N. Psychiatric medication-induced obesity: a review. Obes Rev. 2004;5(4):115-121.